市場調查報告書
商品編碼
1276821
真皮填充劑全球市場規模、份額和行業趨勢分析報告:按類型、產品、最終用途、應用、地區劃分的展望和預測,2023-2029 年Global Dermal Fillers Market Size, Share & Industry Trends Analysis Report By Type, By Product, By End-use (MedSpa, Cosmetic Surgery Clinics and Hospitals), By Application, By Regional Outlook and Forecast, 2023 - 2029 |
真皮填充劑市場規模預計將在 2029 年達到 103 億美元,在預測期內以 8.1% 的複合年增長率增長。
HA 和膠原蛋白是可生物降解的臨時真皮填充劑的兩個示例,使用壽命為 4-9 個月。 不滿和潛在的有害影響都是暫時的。
因此,臨時填充劑始終被用作一線治療,有利於後續使用的長效填充劑。 除了常見的面部皺紋,永久性填充劑主要用於治療皮膚深層皺紋和摺痕。 它被認為是面部年輕化的最佳選擇,尤其是在 HIV 脂肪代謝障礙中。 PMMA 因其有效、持久和安全的效果而被廣泛使用。
COVID-19 影響分析
由於 COVID-19 封鎖,醫用化妝品行業經歷了供應鏈延誤,包括進出口限制、航班取消、減產和供應線中斷。 此外,包括透明質酸和肉毒桿菌毒素在內的非手術治療減少了總使用量。 因此,大流行期間產品需求的下降進一步影響了市場的擴張。 真皮填充劑市場受到 COVID-19 大流行的影響。 然而,在 COVID-19 病例下降後放寬限制將有助於真皮填充劑市場從大流行期間的損失中恢復過來。
市場增長因素
注射填充劑在男性中越來越受歡迎
這個市場中最廣泛的趨勢之一是幾乎所有人群都表現出對微創或非侵入性手術的傾向或傾向。 這對於追求審美美感的男士來說尤為重要。 例如,越來越多的男性發現地心引力和衰老會對他們的面部外觀產生負面影響。 結果,男性選擇了面部填充手術,因為他們成功地逆轉了面部的早期重力老化。 它還具有不需要停機即可恢復的額外好處。
微創方法的增加
在微創手術中,手術是使用範圍和專門的觀察儀器進行的。 減少體積、形狀和不需要的脂肪,同時關注皺紋和細紋等面部異常。 微創技術越來越受歡迎,因為它們幾乎沒有嚴重副作用的風險,需要的切口很少,而且恢復速度很快。 對用於減少皺紋、收緊皮膚、面部輪廓和年輕化的基於能量的微創手術的需求是巨大的。 預計這些因素將推動市場的擴張。
市場製約因素
與真皮填充劑相關的高成本
儘管化妝品應用範圍廣泛,但預計在預測期內市場增長將放緩。 市場增長放緩的主要障礙之一是這些產品的高價標籤。 Derma filler 價格可能因許多變量而異,包括手術類型、從業者的經驗和資格,以及完成手術或治療所需的時間和精力。 因此,與真皮填充劑相關的高成本預計會阻礙市場增長。
產品展望
真皮填充劑市場按產品細分為透明質酸、羥基磷灰石鈣、聚乳酸 (PLLA)、聚甲基丙烯酸甲酯微球等。 在 2022 年的真皮填充劑市場中,羥基磷灰石鈣細分市場贏得了很大的收入份額。 這種增長歸功於其安全特性。 主要參與者在該市場推出新產品也促進了該細分市場的擴張。 氫氧化鈣磷灰石 (CaHA) 會隨著時間的推移刺激膠原蛋白,是可注射真皮填充劑中的活性成分。 它可以提升軟組織下垂,減少下眼瞼下垂,並在不治療淚囊周圍區域的情況下減少淚囊。
按類型劃分的前景
真皮填充劑市場按類型分為可生物降解和不可生物降解。 到 2022 年,可生物降解部分將在真皮填充劑市場佔據最大的收入份額。 這是因為與不可生物降解的類別相比,該細分市場的產品選擇更多,而可生物降解的產品在化妝品中的應用範圍更廣。 該細分市場的增長預計也將受到高產品安全性和穩健監管批准的推動。
使用展望
根據應用,真皮填充劑市場可細分為皺紋矯正、面部輪廓、疤痕治療、豐唇等。 到 2022 年,真皮填充劑市場將由唇部提升部分主導,收入份額顯著。 這是由於大量的唇處理。 微創手術的出現推動了對唇部美容的需求不斷增加,預計這一類別將受到推動。 唇部填充物是一種美容療法,可以增加嘴唇的豐盈度。
結束使用 Outlook
真皮填充劑市場根據最終用戶細分為水療中心、整容手術診所和醫院。 2022 年,醫院部門在真皮填充劑市場的增長率令人鼓舞。 這是由於在醫院進行的面部注射等整容手術的普遍存在。 此外,高科技設備、員工和其他設施的存在增加了信任醫院進行各種填充手術的患者的知名度,從而進一步為該細分市場提供了增長機會。
區域展望
按地區分析了北美、歐洲、亞太地區和 LAMEA 的真皮填充劑市場。 到 2022 年,北美地區將佔據真皮填充劑市場的最高收入份額。 這是由於該地區永恆之美的增長趨勢、其在男性中的日益流行以及對非手術整容手術的日益增長的需求。 在北美,人們非常在意自己的外表和審美標準。 這導致對真皮填充劑的需求不斷增長,以改善面部特徵和減少衰老跡象。
The Global Dermal Fillers Market size is expected to reach $10.3 billion by 2029, rising at a market growth of 8.1% CAGR during the forecast period.
The purpose of dermal fillers is to impart volume and fullness to the skin through injection. A mineral-like substance found in bones called calcium hydroxylapatite, polyalkylimide, hyaluronic acid, polylactic acid, and polymethyl-methacrylate microspheres is among the ingredients utilized in dermal fillers (PMMA).
In addition, the deep dermis, depth of implantation (superficial midterms and upper and subcutaneous levels), the longevity of correction (temporary and permanent), allergenicity, the agent's composition (allografts, semi/fully synthetic, xenografts, or autologous), and stimulatory behavior (physiologic processes of endogenous tissue proliferation) versus replacement fillers are some of the criteria that can be used to classify dermal fillers (space-replacing effect).
HA and collagen are two examples of temporary dermal fillers that are biodegradable and have a lifespan of between four and nine months. Both dissatisfaction and the possibility of detrimental effects are temporary occurrences.
Therefore, in order to save long-lasting fillers for subsequent patient visits, temporary fillers are always employed as the initial line of treatment. Permanent fillers are mostly utilized to treat deep skin wrinkles and furrows that go beyond the scope of typical face creases. They are considered a top choice for face rejuvenation, particularly in HIV lipodystrophy. PMMA is generally employed for effects that are effective, long-lasting, and safe.
COVID-19 Impact Analysis
The medical cosmetics industry experienced supply chain delays due to the COVID-19-imposed lockdowns, which included restrictions on import and export, flight cancellations, decreased production, and disrupted supply lines. Moreover, nonsurgical procedures involving hyaluronic acid and botulinum toxin saw a decline in total usage. Thus, the drop in product demand during the pandemic further impacted the market expansion. The market for dermal fillers has been affected by the COVID-19 pandemic. However, the market for dermal fillers will be driven by the relaxation of regulatory regulations after the decreasing cases of COVID-19, thereby aiding the market to recover after the losses during the pandemic.
Market Growth Factors
The rising popularity of injectable fillers among men
One of the most pervasive trends in the market is that practically all demographic groups have demonstrated a desire or predisposition for these minimally invasive or non-invasive procedures. For the male demographic, who are increasingly using these operations to improve their appearance, this is especially important. For instance, a growing number of men are discovering that gravity and aging can have a detrimental effect on the way their facial features look. As a result, males choose facial filler procedures due to their success in reversing the early gravitational aging of the face. Also, it offers the extra benefit of requiring no downtime for recuperation.
Increasing use of less invasive methods
A scope for seeing and surgical instruments with specialized equipment are used in minimally invasive surgery. It reduces volume, shape, and undesirable fat while concentrating on the abnormalities of the face, such as wrinkles and fine lines. Minimally invasive techniques are becoming more popular because they have almost no risk of significant adverse outcomes and need few or no cuts with quick recovery. There is a huge demand for energy-based, minimally invasive procedures for wrinkle reduction, skin tightening, face contouring, and rejuvenation. These mentioned factors are expected to propel the market's expansion.
Market Restraining Factors
The high cost associated with dermal fillers
The growth of the market is anticipated to be constrained throughout the forecast period, despite the wide range of aesthetic applications. One of the main barriers hindering the slowdown in the expansion of the market is the high price tag attached to these products. Dermal filler prices can vary depending on a variety of variables, including the type of procedure performed, the experience and credentials of the practitioner, and the amount of time and effort necessary to complete the surgery or treatment. Thus, the high cost associated with dermal fillers is expected to hinder the market's growth.
Product Outlook
Based on product, the dermal fillers market is segmented into hyaluronic acid, calcium hydroxylapatite, polylactic acid (PLLA), polymethyl-methacrylate microspheres and others. The calcium hydroxylapatite segment acquired a significant revenue share in the dermal fillers market in 2022. The growth is attributed to its safety characteristics. Key players' launches of new goods in this market also contribute to the segment's expansion. Calcium hydroxylapatite (CaHA), which stimulates collagen over time, is an active constituent in the injectable dermal filler. Without treating the area around the tear trough, one can lift sagging soft tissues, lessen lower eyelid lag, and decrease the tear trough.
Type Outlook
On the basis of type, the dermal fillers market is divided into biodegradable and non-biodegradable. The biodegradable segment witnessed the largest revenue share in the dermal fillers market in 2022. This is due to the presence of more product options in this segment than in the non-biodegradable category and because biodegradable products have more varied aesthetic uses. The segment's expansion is also anticipated to be aided by the goods' higher level of safety and solid regulatory approval.
Application Outlook
By application, the dermal fillers market is classified into wrinkle correction, facial contouring, scar treatment, lip enhancement and others. The lip enhancement segment garnered a prominent revenue share in the dermal fillers market in 2022. This is due to the strong volume of lip procedures. The category is anticipated to be driven by the increased demand for cosmetic enhancements of the lips, fueled by the advent of minimally invasive procedures. Lip fillers are a cosmetic treatment that can enhance the volume of lips.
End-Use Outlook
Based on the end-use, the dermal fillers market is bifurcated into MedSpa, cosmetic surgery clinics and hospitals. The hospital segment recorded a promising growth rate in the dermal fillers market in 2022. This is owing to the widespread use of aesthetic procedures like face injectables carried out in hospitals. In addition, the presence of high-tech equipment, staff and other facilities increased their popularity among patients who trust hospitals for various types of filler surgeries, and thus further providing growth opportunities for the segment.
Regional Outlook
Region-wise, the dermal fillers market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the dermal fillers market in 2022. This is due to the region's developing trend of ageless beauty, increased popularity among men, and rising desire for non-surgical aesthetic procedures. In North America, people care a lot about their looks and beauty standards. Due to this, there is a significant demand for dermal fillers to improve face characteristics and lessen aging symptoms.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioplus Co. Ltd, Bioxis pharmaceuticals, Suneva Medical, Inc., Galderma S.A., Allergan PLC (AbbVie, Inc.), Sinclair Pharma Ltd. (Huadong Medicine Co., Ltd.), Revance Therapeutics, Inc., Medytox Inc., Merz Pharma GmbH & Co. KGaA and Prollenium Medical Technologies Inc.
Strategies Deployed in Dermal Fillers Market
Mar-2023: Galderma revealed FACE by Galderma, an aesthetic visualization tool that enables aesthetic professionals and patients to visualize injectable treatment results. The FACE by Galderma would enable aesthetic professionals to identify and tailor an individualized treatment plan to meet the needs and aesthetic goals of each patient.
Oct-2022: Prollenium Medical Technologies took over SoftFil, the cosmetic aesthetic leader. This acquisition results in creating synergies between the two brands and further expands and strengthens its presence in international markets.
Sep-2022: Revance Therapeutics received US FDA clearance for its DAXXIFY (DaxibotulinumtoxinA-lanm). The approved product provides temporary improvement of moderate to severe frown lines in adults. 2020-Jan: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Feb-2022: Merz Aesthetics released Radiesse® (+) Lidocaine injectable implant for soft tissue augmentation, enhancing mild to severe jawline contour loss in adults over 21. The launch is aimed at meeting the demand of patients seeking a more defined and contoured jawline.
Jan-2022: Galderma completed the acquisition of ALASTIN Skincare®, Inc, which provides a collection of cutting-edge products for optimal procedure results and daily skincare regimens. The acquisition would enhance the dermatology platform of Galderma with a comprehensive collection of scientifically proven products for daily skincare regimens and post-operative care and reinforce the company's commitment to being aesthetic professionals' partner of choice.
Sep-2021: Galderma joined hands with Sofregen Medical, Inc., a medical device company that uses silk protein for tissue building and regeneration. This collaboration would enhance Galderma's capability to build on decades of biostimulation and hyaluronic acid (HA) filler innovation.
Jun-2021: Medytox received approval from the Taiwan Food and Drug Administration for marketing its botulinum toxin Meditoxin in Taiwan. The Approval would allow the company to expand its business in Southeast Asian countries.
Feb-2021: Sinclair Pharma unveiled Lanluma V, for the face and hands and Lanluma X for the rest of the body. The new products are designed to stimulate collagenases to improve the skin's inner structure and shape, reshape and enhance the fullness of different areas of the body, and reduce cellulite.
Oct-2020: Allergan took over Luminera's dermal filler business. The addition of Luminera's entire dermal portfolio and R&D pipeline improves the acquiring company's dermal filler offerings. Further, Luminera's assets perfectly complement Allergan's JUVEDERM® filler franchise.
Sep-2020: Suneva Medical, Inc. entered into a partnership with Neauvia North America, a subsidiary of Neauvia, a global aesthetics brand. Through this partnership, the company would provide Neauvia North America's Plasma IQ throughout North America. Plasma IQ complements Suneva Medical's portfolio of facial regenerative aesthetics products that would enable the company to offer proven and validated solutions for aesthetic providers and their patients.
Jun-2020: Galderma launched Restylane Kysse, a newly approved lip filler. The Restylane Kysse is a hyaluronic acid (HA) filler that is proven to last for up to 1 year. The product is approved for lip augmentation and the correction of wrinkles around the upper lips.
Jan-2020: Revance entered into an agreement with Teoxane SA, a Swiss developer of aesthetic medicine. The agreement includes Revance acting as an exclusive distributor for Teoxane's dermal filler products.
Sep-2019: Merz expanded its geographical footprint by opening a manufacturing site in Dessau. The new production plant would cater to the evolving demand for its Belotero dermal fillers. Moreover, the location of the new facility to secure the international supply of its medical aesthetics products.
Apr-2019: Merz revealed Belotero Revive, a dermal filler product that contains a combination of hyaluronic acid (HA) and glycerol. The Belotero® Revive is designed to enhance hydration, elasticity, and firmness of the skin and to address the appearance of fine lines.
Market Segments covered in the Report:
By Type
By Product
By End-use
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures